Testing a flexible dose of immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery or other local treatments, or that has gotten worse after those treatments.
- You must not have had prior treatment with certain immunotherapy drugs (PD-1, PD-L1, or CTLA-4 blockers).
- Your liver function must be at a moderate level, called Child-Pugh B7 or B8 on a standard blood test.
- You need to have at least one tumor that can be measured on a scan (like a CT or MRI).
- Your blood counts and organ function must be within a certain range (for example, platelets at least 40,000, hemoglobin at least 8, and adequate kidney function).
- You must be 18 years or older and not have a history of an organ transplant, active autoimmune disease that needs treatment, or a serious allergy to IV contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.